Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives

被引:272
|
作者
Zhang, Rui Xue [1 ]
Wong, Ho Lun [2 ]
Xue, Hui Yi [2 ]
Eoh, June Young [2 ]
Wu, Xiao Yu [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON M5S 2S2, Canada
[2] Temple Univ, Sch Pharm, 3304 North Broad St, Philadelphia, PA 19140 USA
关键词
Nanomedicine; Synergistic drug combinations; Cancer therapy; Strategies; Perspectives; METASTATIC BREAST-CANCER; OVERCOMING MULTIDRUG-RESISTANCE; ANTI-SURVIVIN SIRNA; CO-DELIVERY; IN-VITRO; POLYMERIC MICELLES; ANTICANCER DRUGS; SOLID TUMORS; MITOMYCIN-C; NANOPARTICLE FORMULATION;
D O I
10.1016/j.jconrel.2016.06.012
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:489 / 503
页数:15
相关论文
共 50 条
  • [41] Nanomedicine for Cancer Therapy
    Amiji, Mansoor M.
    PHARMACEUTICAL RESEARCH, 2011, 28 (02) : 181 - 186
  • [42] Synergistic Nanomedicine: Passive, Active, and Ultrasound-Triggered Drug Delivery in Cancer Treatment
    Elkhodiry, Mohamed A.
    Momah, Christian C.
    Suwaidi, Shaima R.
    Gadalla, Dina
    Martins, Ana M.
    Vitor, Rute F.
    Husseini, Ghaleb A.
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2016, 16 (01) : 1 - 18
  • [43] Nanomedicine for Cancer Therapy
    Mansoor M. Amiji
    Pharmaceutical Research, 2011, 28 : 181 - 186
  • [44] Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy
    Xu, Xiaoxuan
    Wu, Yao
    Qian, Xindi
    Wang, Yuqi
    Wang, Jiaoying
    Li, Jie
    Li, Yaping
    Zhang, Zhiwen
    ADVANCED HEALTHCARE MATERIALS, 2022, 11 (01)
  • [45] Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy
    Dent, Paul
    Curiel, David T.
    Fisher, Paul B.
    Grant, Steven
    DRUG RESISTANCE UPDATES, 2009, 12 (03) : 65 - 73
  • [46] Programmable nanomedicine: synergistic and sequential drug delivery systems
    Pacardo, Dennis B.
    Ligler, Frances S.
    Gu, Zhen
    NANOSCALE, 2015, 7 (08) : 3381 - 3391
  • [47] Applications of Nanomedicine in Brain Tumor Therapy: Nanocarrierbased Drug Delivery Platforms, Challenges, and Perspectives
    Verma, Ravinder
    Rao, Lakshita
    Kumar, Harish
    Bansal, Nitin
    Deep, Aakash
    Parashar, Jatin
    Yadav, Manish
    Mittal, Vineet
    Kaushik, Deepak
    RECENT PATENTS ON NANOTECHNOLOGY, 2025, 19 (01) : 99 - 119
  • [48] Perspectives on Strategies for Overcoming Cancer Therapy Resistance
    Wu, Zhiqiang
    Han, Weidong
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2015, 16 (04) : 268 - 269
  • [49] Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
    Kyuho Han
    Edwin E Jeng
    Gaelen T Hess
    David W Morgens
    Amy Li
    Michael C Bassik
    Nature Biotechnology, 2017, 35 : 463 - 474
  • [50] Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
    Han, Kyuho
    Jeng, Edwin E.
    Hess, Gaelen T.
    Morgens, David W.
    Li, Amy
    Bassik, Michael C.
    NATURE BIOTECHNOLOGY, 2017, 35 (05) : 463 - +